---
title: 'Medical Director, Clinical Development at Prime Medicine'
canonical: 'https://feeny.ai/job/medical-director-clinical-development-prime-medicine-cambridge-mez51gt08bys'
type: 'job'
last_seen: '2026-09-10'
---

# Medical Director, Clinical Development at Prime Medicine

- **Company:** Prime Medicine
- **Location:** Cambridge, MA
- **Compensation:** $272k–$302k
- **Posted:** 2026-09-10
- **Last confirmed live:** 2026-09-10
- **Apply:** https://job-boards.greenhouse.io/primemedicine/jobs/6187978004

## Job description

Company Overview:

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types.

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: hematology, immunology & oncology, liver and lung. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. For more information, please visit [www.primemedicine.com](http://www.primemedicine.com/).

Position Overview:

We are seeking a physician-scientist with an interest and/or background in gene therapy to lead Prime Medicine’s programs from pre-clinical development into the clinic.  The medical director will serve an integral role in the clinical development organization.  They will interact broadly across the organization with research and with regulatory affairs in order to implement Prime’s strategies across one or more therapeutic areas.  In concert with the clinical operations and clinical sciences teams, they will be responsible for the development, implementation and execution of clinical trials across multiple therapeutic areas.  They will act as a representative of Prime Medicine in interactions with key opinion leaders, site investigators and regulators.  The medical director will report to clinical development leadership.

Key Responsibilities:

- In collaboration with research, clinical sciences, regulatory affairs and clinical operations, develop a clinical trials strategy for the efficient and safe introduction of Prime gene editing therapeutics into human study participants, through in-human proof-of-concept.
- With support from clinical sciences and medical writing, conceptualize and author clinical trials protocols, including observational and all interventional trials from phase I - IV
- Serve as medical monitor, responsible for interfacing with site investigators, overseeing patient safety and analyzing data from clinical trials
- Represent clinical development on cross functional program teams
- Organize Scientific Advisory Boards and solicit feedback from Key Opinion Leaders
- Support Prime Medicine regulatory interactions both in the formulation of regulatory documents and in face-to-face discussions with regulators
- Collaborate with pre-clinical research to implement a translational biomarkers program for all clinical trials, and analyze translational data from Prime Medicine’s trials.
- Attend scientific and medical conferences as needed, to support presentation of Prime Medicine data and/or acquire state-of-the-art information in a relevant therapeutic field.
- Travel to investigator sites, regulatory meetings and conferences will be required.  Must be able to travel up to 25%.

Qualifications:

- M.D. or equivalent degree, preferably M.D.-PhD
- Minimum 3+ years industry or equivalent academic experience, either overseeing clinical trials or performing relevant research
- Track record of scientific and medical excellence
- Rigorous understanding of core scientific concepts in gene therapy, genetics and immunology
- Specialization in Pulmonology or Hepatology preferred, but not required.  Broad medical knowledge and facility with novel medical concepts is required.
- Basic understanding of Good Clinical Practice
- Facility and comfort with standard statistical methodologies and analytical tools
- Strong communication skills, with demonstrated experience composing scientific publications and delivering oral presentations.
- Ability to work in a heavily matrixed, cross-functional environment

The pay range reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on several factors including, but not limited to, relevant experience, skills, and education. This role is eligible for an annual short-term incentive award (e.g., bonus) and an annual long-term incentive award (e.g., equity).

Prime Medicine offers a comprehensive Total Rewards package with robust health, financial, and wellness benefits—including medical, dental, vision, life insurance, a 401(k) match, and equity programs—along with generous paid time off, wellness days, and company-wide recharge breaks.

Our commitment to employee well-being reflects our belief that when we care for our people, we strengthen our ability to put patients first and make meaningful impact together.

U.S. Pay Range $272,000—$302,000 USD

Prime Medicine is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, age, sexual orientation, gender identity, disability, veteran status, or any other classification protected by law.

## About Prime Medicine

## Company Overview
- **One-liner**: Prime Medicine is a biotechnology company using prime editing, a next-generation gene editing technology, to “search and replace” disease-causing genetic mutations and restore normal gene function.
- **Entity Type**: Public (NASDAQ: PRME, IPO October 2022)
- **Headquarters**: Cambridge, Massachusetts, United States
- **Founded**: 2019
- **Founders**: David Liu, PhD (Scientific Founder); Andrew Anzalone, MD, PhD (Co-founder)

## Core Business
- **Primary industry**: Biotechnology / Gene Editing Therapeutics
- **Target customers**: Patients with genetic diseases; partners include pharmaceutical companies (e.g., Bristol Myers Squibb) and foundations (e.g., Cystic Fibrosis Foundation)
- **Mission**: “To bring the promise of gene editing to patients” and ultimately “cure, halt, and prevent genetic diseases, providing lifelong benefit to patients.”

## Products & Services
- **Prime Editing Platform**: A proprietary gene editing technology that acts like a “DNA word processor” to precisely replace faulty DNA sequences without causing double-strand breaks. Designed to address ~90% of known disease-causing mutations.
- **PM359** (Phase 1/2): Ex vivo prime editing therapy for p47phox Chronic Granulomatous Disease (CGD). Received FDA RMAT designation and orphan drug designation.
- **PM577a** (Phase 1/2): In vivo prime editing therapy for H1069Q-mutated Wilson Disease. Clinical trial application cleared in New Zealand.
- **Alpha-1 Antitrypsin Deficiency (AATD)**: Discovery-stage liver program using LNP delivery.
- **Cystic Fibrosis**: Discovery program supported by Cystic Fibrosis Foundation (up to $15M), using PASSIGE™ technology.
- **Ex vivo CAR-T** (collaboration with Bristol Myers Squibb): Strategic license and broad collaboration to develop and commercialize ex vivo T-cell prime editor products.

## Market Standing
- **Valuation/Market Cap**: $777.8 million (as of mid-2026, per LinkedIn data)
- **Key Metric**: Annual revenue $4.6 million; total funding raised ~$1.02 billion (including post-IPO equity)
- **Notable Investors/Partners**: ARCH Venture Partners, F-Prime, Bristol-Myers Squibb (corporate round $55M in 2024), Google Ventures (post-IPO equity $5M in 2025), Cystic Fibrosis Foundation
- **Growth Signals**: 
  - Clinical data for PM359 published in *The New England Journal of Medicine*; RMAT designation from FDA.
  - Headcount of 154 (down 29.4% YoY, likely reflecting strategic refocusing).
  - Active job postings: 7 (as of mid-2026), with recent uptick in quarterly postings (+40%).

## Competitive Advantages
- **Prime Editing differentiation**: Unlike CRISPR, prime editing does not require double-strand DNA breaks, enabling more precise and predictable edits with fewer unwanted modifications.
- **Broad applicability**: Can theoretically correct ~90% of known disease-causing mutations across many organs and cell types.
- **Strong IP and scientific foundation**: Co-invented by David Liu (Broad Institute), a pioneer in gene editing.

## Strategic Focus
- **Advancing lead programs** (PM359 for CGD, PM577a for Wilson Disease) through clinical development and regulatory approvals.
- **Expanding pipeline** in liver, lung, hematology/immunology/oncology via internal research and strategic partnerships (e.g., BMS for CAR-T).
- **Leveraging delivery technologies** (LNP, AAV, ex vivo electroporation) to enable both in vivo and ex vivo applications.

## Why Work Here
- **Mission-driven culture**: Opportunity to shape the future of gene editing and directly impact patients with genetic diseases.
- **Collaborative environment**: Emphasis on diversity of viewpoints, scientific curiosity, and passion for patient outcomes.
- **Location**: Headquarters in Cambridge, MA – a hub for biotech innovation. Presence also in India.
- **Career development**: Roles span research, clinical, technical development, finance, HR, and informatics. Recent job postings include AI & Informatics Engineer, Senior Scientist, and Director of People & Culture.
- **Perks & culture**: Not explicitly detailed, but the company values “dedicated, scientifically curious individuals” and offers the chance to work with a world-class scientific team.

## Sources
1. [primemedicine.com](https://primemedicine.com/)
2. [primemedicine.com/about/](https://primemedicine.com/about/)
3. [primemedicine.com/careers/](https://primemedicine.com/careers/)
4. [primemedicine.com/pipeline/](https://primemedicine.com/pipeline/)
5. [linkedin.com/company/prime-medicine](https://www.linkedin.com/company/prime-medicine)

## Other roles at Prime Medicine

- [Senior Quality Engineering Specialist](https://feeny.ai/job/senior-quality-engineering-specialist-prime-medicine-cambridge-yearqxvgjzt1) — Cambridge, MA
- [Informatics Engineer](https://feeny.ai/job/informatics-engineer-prime-medicine-cambridge-t211ebww167m) — Cambridge, MA
- [Senior Scientist / Senior Engineer, LNP Process Development](https://feeny.ai/job/senior-scientist-senior-engineer-lnp-process-development-prime-medicine-h2ma4d77ffav) — Cambridge, MA
- [Senior Scientist, mRNA Design & Platform Innovation](https://feeny.ai/job/senior-scientist-mrna-design-platform-innovation-prime-medicine-cambridge-hma82924aerh) — Cambridge, MA
- [Senior Director, Biometrics](https://feeny.ai/job/senior-director-biometrics-prime-medicine-cambridge-5b24s6r19ew4) — Cambridge, MA
- [Medical Director, Clinical Development](https://feeny.ai/job/medical-director-clinical-development-kailera-therapeutics-inc-united-states-c4kp9yagj1rx) — United States
- [Medical Director, Clinical Development](https://feeny.ai/job/medical-director-clinical-development-dyne-therapeutics-waltham-bjcvm54mvn7y) — Waltham, MA
- [Medical Director, Clinical Development](https://feeny.ai/job/medical-director-clinical-development-kailera-therapeutics-inc-waltham-zrc43zkxh0y6) — Waltham, MA